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Background: We conducted a prospective, randomized, multicenter study to evaluate the differences in the
blocking effect of different doses of rocuronium between sevoflurane- or propofol-remifentanil anesthesia in an
Asian population.
Methods: A total of 368 ASA I–II patients was enrolled. Anesthesia was induced with 2.0 mg/kg propofol and 0.
1 μg/kg/min remifentanil (TIVA) or 5.0 vol.% sevoflurane with 0.1 μg/kg/min remifentanil (SEVO). Tracheal intubation
was facilitated at 180 s after the administration of rocuronium at 0.3, 0.6, or 0.9 mg/kg and then intubation
condition was evaluated. The time to maximum block and recovery profile were monitored by TOF stimulation of
the ulnar nerve and by recording the adductor pollicis response using acceleromyography.
Results: The numbers of patients with clinically acceptable intubation conditions were 41, 82, and 97 % (TIVA) and
34, 85, and 90 % (SEVO) at each dose of rocuronium, respectively. There were no significant differences in the time
to maximum block between groups at each rocuronium dose. There were significant differences in the recovery to
a train-of-four ratio of 90 % between the groups: 42.7 (19.5), 74.8 (29.9), and 118.4 (35.1) min (TIVA) and 66.5 (39.3),
110.2 (43.5), and 144.4 (57.5) min (SEVO) at 0.3, 0.6, and 0.9 mg/kg, respectively (P < 0.001).
Conclusions: There are no significant differences in intubation conditions between propofol-remifentanil and
sevoflurane-remifentanil anesthesia at the same dose of rocuronium. The type of anesthetic does not significantly
influence the time to maximum block by rocuronium. Rocuronium at a dose of 0.9 mg/kg should be used for
better intubation conditions with both anesthesia regimens in an Asian population.
Trial registration: UMIN-CTR Clinical Trial (http://www.umin.ac.jp/ctr/index.htm; UMIN#000007289; date of registration
14th February 2012).
Keywords: Anesthetics inhalation, Sevoflurane, Anesthetics intravenous, Propofol, Remifentanil, Neuromuscular
blocking agents, Rocuronium, Monitoring, Onset, Duration of action, Intubation condition
Abbreviations: ANOVA, Analysis of variance; ASA, American Society of Anesthesiology; BIS, Bispectral index; ED95, 95 %
effective dose; SEVO, Sevoflurane; TIVA, Total intravenous anesthesia; TOF, Train-of-four* Correspondence: hsyang@amc.seoul.kr
2Department of Anesthesiology and Pain Medicine, Seoul Asan Medical
Center, University of Ulsan, College of Medicine, 88 Olympic-ro 43-gil,
Songpa-gu, Seoul 138-736, Korea
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lee et al. BMC Anesthesiology  (2016) 16:65 Page 2 of 7Background
Rocuronium bromide is a monoquaternary, aminoster-
oid, non-depolarizing, muscle relaxant. Its main ad-
vantage compared with other currently available
muscle relaxants is its rapid onset time and inter-
mediate duration of action. The standard dose (2 ×
ED95, 0.6 mg/kg) of rocuronium is reported to pro-
vide clinically acceptable (good or excellent) intub-
ation conditions in all patients at 90 s after
administration, and is comparable to 1 mg/kg (3 ×
ED95) of succinylcholine [1]. Clinically, anesthesiolo-
gists in Korea and Japan have sometimes experienced
unacceptable intubation conditions after administra-
tion of a standard dose of rocuronium. It is unknown
whether the ethnicity of the patient can directly affect
rocuronium potency but Dahaba et al. [2] have re-
ported geographic regional differences in the rocuro-
nium dose–response relation and time course of
action. They have shown that the ED95 of rocuronium
is significantly higher in Chinese patients than in
American patients (475 ± 155 μg/kg vs 362 ± 149 μg/
kg, respectively). Hence, the standard dose of rocuro-
nium might not provide clinically acceptable intub-
ation conditions in Asian patients. The first purpose
of this study was thus to evaluate the intubation con-
ditions at 180 s after administration of three different
doses of rocuronium to investigate whether 0.6 mg/kg
was sufficient in a population of Asian patients.
The potentiation of the neuromuscular blocking
effects of muscle relaxants by inhalational anesthetics is
well known [3–5]. Consequently, inhalational anesthetics
can decrease the dose requirement of muscle relaxants
and prolong both the duration of action and recovery
from neuromuscular block. The dose-response curves of
rocuronium under sevoflurane, isoflurane, or desflurane
shifts to the left compared with those obtained during
propofol anesthesia [4]. The interaction of inhalational
anesthetics and muscle relaxants is a time-dependent
phenomenon and the potentiation effect varies among
inhalational agents [5]. Sevoflurane markedly potentiates
muscle relaxants, shortening the onset time compared
with other anesthetics. Such potentiation is not clear
during induction and only becomes significant during
prolonged anesthesia [6]. Thus, the second purpose of
this study was to compare time to maximum block, and
recovery profiles of rocuronium between sevoflurane-
remifentanil and propofol-remifentanil anesthesia.
Methods
Patients
This study was a prospective, multicenter, randomized,
single-blind, parallel-group study performed in the South
Korea and Japan (2 sites). After obtaining institutional
review board approval (#016 at Higashi Omiya GeneralHospital and #2011-0697 at Asan Medical Center);
registered with the UMIN clinical trial registry (www.u-
min.ac.jp), number UMIN#000007289 and written in-
formed consent, we enrolled 368 Korean or Japanese
ASA I or II patients, aged 20 to 80 years who would be
undergoing elective general surgery with about 2 h of
surgical duration (ex, laparoscopic cholecystectomy, lap-
aroscopic appendectomy, simple mastectomy and etc.)
under general anesthesia at Higashi Omiya General Hos-
pital, Saitama, Japan and Seoul Asan Medical Center,
Seoul, South Korea from February 2012 to February
2013. Using a sealed envelope method, 368 patients were
randomly assigned to a sevoflurane (SEVO) or total
intravenous anesthesia (TIVA) group. They were then
randomly assigned to a rocuronium 0.3, 0.6, or 0.9 mg/
kg subgroup (Fig. 1). Exclusion criteria were as follows:
hepatic, renal, cardiac, respiratory, neurologic, or neuro-
muscular disease, hypertension, obesity (body mass
index greater than 30), pregnancy, and drug allergies.
The patients with Mallampati classification grade 3/4 or
ones who were expected difficulties during intubation or
laryngoscopic manipulation were excluded. In addition,
any patients taking medications affecting neuromuscular
blockade, such as anticonvulsants, anti-arrhythmic, and
magnesium, were also excluded.Anesthesia technique and measurements
Anesthesia was induced with 2.0 mg/kg propofol and
0.1 μg/kg/min remifentanil (TIVA group) or 5.0 vol.%
sevoflurane with 0.1 μg/kg/min remifentanil (SEVO
group), and maintained with 4.0 mg/kg/h propofol
and 0.1–0.5 μg/kg/min remifentanil (TIVA group) or
1.5–3.0 vol.% sevoflurane with 0.1–0.5 μg/kg/min
remifentanil (SEVO group). Rocuronium was adminis-
trated when we confirmed the loss of consciousness
after administration of propofol by checking the eye-
lash reflex and BIS under 40–50. If the patients
would be still awake at 2 min after administration of
propofol, additional propofol 0.5 mg/kg would be
given. The supplement was not needed. Tracheal in-
tubation using direct laryngoscopy with Macintosh
blade without stylet was performed at 180 s after ad-
ministration of rocuronium at 0.3, 0.6, or 0.9 mg/kg.
The anesthesiologists who were blind to the sub-
groups, performed the intubation and assessed the in-
tubating conditions and Cormack-Lehane (C-L) score.
The intubation conditions as a primary endpoint were
evaluated at 180 s after the administration of rocuro-
nium using a modified grading system based on the
system of Fuchs-Buder et al. [7] (Table 1). Systolic
and diastolic blood pressure, heart rate, and bispectral
index were measured before anesthesia and at 1, 3,
and 5 min after intubation.
Fig. 1 Flow diagram of the inclusion and exclusion criteria used in this study
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Neuromuscular function was assessed using acceleromyo-
graphy of the adductor pollicis muscle (TOF-Watch; Or-
ganon Ltd., Dublin, Ireland) according to the guidelines of
Fuchs-Buder et al [7]. After loss of consciousness (BIS
value < 60), neuromuscular monitoring began immediatelyTable 1 Grade of intubating condition
Grade Jaw relaxation Vocal cord
Excellent Good Immobile
Good Good Moving
Poor Good Moving or a
Impossible Poor Closed
Modified from Fuchs-Buder et al.[7]with train-of-four (TOF) stimulation (0.2 ms duration, fre-
quency 2 Hz, 2 s duration with supramaximal current, re-
peated every 15 s). As a secondary outcomes, the time to
maximum block of rocuronium (sec), recovery index (T25
to T75, sec), and the time required for the TOF ratio to re-
cover to 90 % (T90, sec) were measured.Response to intubation
None
Minimal diaphragmatic movement only
ctively closing Coughing or bucking
Intubation not possible
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We analyzed intubation conditions, time to maximum
block, recovery index, and time to T90 recovery using one-
way analysis of variance (ANOVA) followed by post-hoc
multiple comparison with Bonferroni’s correction. Blood
pressure, heart rate, and bispectral index during anesthesia
were analyzed using repeated measured ANOVA followed
by within-/between-group multiple comparison as a post-
hoc test. We expected that one grade of difference in the
ease of intubation would make a clinically significant im-
provement in the intubation condition. We needed a total
300 patients to achieve 90 % power and 5 % significance
level which can provide a significant difference between
more than 3 groups. To allow for dropouts as 20 %, sam-
ple size was increased to 60 patients in each group. We
analyzed the data using SAS/STAT® software version 8.2
(SAS Institute Inc., Cary, NC) and GraphPad Prism ver-
sion 6.00 for Windows (GraphPad Software, La Jolla, CA).
A P-value < 0.05 was considered statistically significant.
Results
All data are expressed as mean (SD) or number of pa-
tient (%) or median (minimum-maximum). Patient char-
acteristics were shown in Table 2. There was no
significant difference in C-L score between groups
(Table 3). The BIS values were significantly decreased
after anesthesia induction compared with baseline (be-
fore anesthesia) (P < 0.001) and the SEVO groups
showed significantly lower values than the TIVA groups
(P < 0.001) [data not shown]. The hemodynamic values
(systolic and diastolic blood pressure, heart rate) also
significantly decreased at 1, 3, and 5 min after intubation
compared with baseline (before anesthesia) in both
groups (P < 0.001), while the systolic/diastolic blood
pressure and heart rate of the SEVO groups were signifi-
cantly lower than those of the TIVA groups at 3 and
5 min after intubation [data not shown]. However, con-
cerning values at 1 min after intubation as anesthetic
depth of the intubation condition, there was no signifi-
cant difference in diastolic blood pressure, heart rate
and BIS except systolic blood pressure between groups
(P > 0.05, Table 3).
Intubating conditions were significantly different







Age (yrs) 51.3 (16.5) 54.8 (15.6) 61.9 (9
Sex (M/F) 23 / 41 23 / 39 10 / 4
Height (cm) 160.5 (10.4) 160.9 (11.0) 155.6
Weight (kg) 64.4 (12.5) 68.2 (12.6) 62.2 (9
Data are expressed as mean (SD) or number of patientsat the different doses of rocuronium (Table 3).
However, there were no significant differences
between the TIVA and SEVO groups at the same
dose of rocuronium.
Larger doses of rocuronium significantly shortened the
time to maximum block (Table 4). The differences be-
tween groups were not significant at the same dose of
rocuronium. Larger doses of rocuronium significantly
increased the recovery index in each group. The SEVO
group showed a significantly longer recovery index than
the TIVA group at the same dose of rocuronium. Larger
doses of rocuronium showed a significantly longer re-
covery time to a TOF ratio of 90 % in both TIVA and
SEVO groups. At the same dose of rocuronium, the
SEVO group showed a longer recovery time to a TOF
ratio of 90 % than the TIVA group.
Discussion
The results of our current study show that sevoflurane
and propofol do not have different actions on the onset
of the effects of rocuronium or on intubation conditions.
However, sevoflurane significantly prolongs the duration
of action of rocuronium compared with propofol. In
addition, 0.9 mg/kg rocuronium was necessary to
achieve adequate conditions for intubation under both
propofol- and sevoflurane-remifentanil anesthesia in an
Asian population.
Previously, Dahaba et al. [2] reported that there is a
significant difference in rocuronium potency and dur-
ation of action among Austrian, Chinese, and American
patients. According to their report, the ED95 of rocuro-
nium in Chinese patients is 0.48 ± 1.6 mg/kg, which is
significantly higher than the dose in American patients
(0.36 ± 1.5 mg/kg). We show in our current investigation
that clinically acceptable intubation conditions were
achieved for 82 % (TIVA group) and 85 % (SEVO group)
of patients after 0.6 mg/kg of rocuronium. However, for
0.9 mg/kg of rocuronium, 97 % (TIVA group) and 90 %
(SEVO group) of patients showed acceptable intubation
conditions (P < 0.001) and there was no difference be-
tween the types of anesthetic. Hence, we confirmed that
the administration of 0.9 mg/kg of rocuronium can pro-
vide better intubation conditions under both propofol-
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9 27 / 34 29 / 33 20 / 40
(7.8) 161.8 (10.1) 161.6 (9.7) 159.8 (10.3)
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Excellent 2 (3) 18 (29) 41 (68) 5 (8) 25 (40) 43 (72) <0.001*
Good 24 (38) 33 (53) 17 (28) 16 (26) 28 (45) 11 (18)
Poor 12 (19) 8 (13) 1 (2) 22 (36) 7 (11) 5 (8)
Impossible 26 (41) 3 (5) 1 (2) 18 (30) 2 (3) 1 (2)
Acceptable 26 (41) 51 (82) 58 (97) 21 (34) 53 (85) 54 (90) <0.001*
Unacceptable 38 (59) 11 (18) 2 (3) 40 (66) 9 (15) 6 (10)
C-L score 1 (1–2) 1 (1–2) 1 (1–3) 1 (1–2) 1 (1–3) 1 (1–2) >0.05**
SBP (mmHg) 115 ± 19 120 ± 21 116 ± 21 106 ± 20 110 ± 21 102 ± 19 >0.05**
DBP (mmHg) 70 ± 12 70 ± 13 68 ± 15 63 ± 14 66 ± 12 64 ± 13 >0.05**
HR (bpm) 72 ± 13 72 ± 14 74 ± 13 67 ± 13 68 ± 11 71 ± 13 >0.05**
BIS 44 ± 11 43 ± 14 41 ± 11 40 ± 13 42 ± 13 38 ± 11 >0.05**
All data are expressed as number of patients (%) or median (minimum-maximum). C-L score; Cormack-Lehane score for the grading of direct laryngoscopy. SBP;
systolic blood pressure at 1 min after intubation. DBP; diastolic blood pressure at 1 min after intubation. HR; heart rate at 1 min after intubation. BIS; bispectral
index at 1 min after intubation
* The difference within and between groups (TIVA and SEVO groups) at the same dose of rocuronium
There were no significant differences between the TIVA and SEVO groups at the same dose of rocuronium (P = 0.065 at 0.3 mg/kg, P = 0.612 at 0.6 mg/kg, and
P = 0.262 at 0.9 mg/kg)
** There was no significant difference in C-L grade between groups (P > 0.05). There was also no significant difference in SBP, DBP, HR and BIS at 1 min after
intubation between groups (P > 0.05)
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potentiate the neuromuscular effects of rocuronium.
The mechanism by which inhalational anesthetics po-
tentiate the effects of muscle relaxants is unknown. The
proposed mechanisms include a central effect on alpha-
motor neurons and interneuronal synapses [8], inhib-
ition of postsynaptic nicotinic acetylcholine receptors
[9], or augmentation of the antagonist’s affinity at the re-
ceptor site [10]. In addition, more than one mechanism
is simultaneously involved and different inhalational an-
esthetics may not act exactly in the same way [11].
Such potentiation is not evident during induction and
only becomes significant as the anesthesia duration be-
comes more prolonged [6]. In a study to quantify the
relationship between the dose–response curve of vecur-
onium and the duration of exposure to an end-tidal con-
centration of sevoflurane, Suzuki et al. [5] showed that
the duration of sevoflurane anesthesia influenced the
dose–response of vecuronium and that 30 min inhal-
ation of 1.7 % end-tidal concentration was sufficient to







Maximum block (sec) 260.6 (130.1) 149.8 (62.5) 107.4
Recovery index (T25-T75) (min) 11.4 (4.4) 16.0 (4.6) 27.3 (8
Recovery to T90 (min) 42.7 (19.5) 74.8 (29.9) 118.4
All data are expressed as mean (SD)
*Differences within groups (TIVA group or SEVO group)
**Differences between groups at the same dose of rocuroniumto 80 min was required to achieve maximal neuromuscu-
lar effects under 1 MAC halothane and isoflurane [12].
No report to date has shown that propofol could clin-
ically potentiate neuromuscular blocking effects, but
propofol has been reported to potentiate the effects of
vecuronium, pancuronium, and suxamethonium in vitro
[13]. Interestingly, intravenous anesthetics may have a
direct effect on skeletal muscle [14]. Opioids are com-
monly used for anesthesia and are often administered
with muscle relaxants. Opioids theoretically could affect
neuromuscular blocking agents by reducing acetylcho-
line release [15]. However, we used remifentanil similarly
in both our SEVO and TIVA groups and, therefore, the
effects of remifentanil can be assumed the same in both
groups.
We find from our current analyses that the type of
anesthetic did not influence the time to maximum block.
At the same dose of rocuronium, the mean time was
similar between the TIVA and SEVO groups, but a
higher dose of rocuronium shortened the time to max-








(43.3) 265.5 (143.0) 165.8 (91.8) 110.6 (38.8) <0.001*
.5) 20.7 (16.5) 33.8 (20.6) 47.1 (20.7) <0.001*,**
(35.1) 66.5 (39.3) 110.2 (43.5) 144.4 (57.5) <0.001***
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tween the TIVA and SEVO groups at the same dose of
rocuronium and that an increased rate of acceptable in-
tubation conditions occurred with larger doses of rocur-
onium in both groups. These findings are in agreement
with those reported by Lowry et al. [16], which showed
that the onset time of mivacurium did not differ between
sevoflurane and propofol. Ahmed et al. [17] also re-
ported that an increase in sevoflurane exposure time did
not shorten the time to maximum block. However,
Yamaguchi et al. [18] reported that 8 % sevoflurane in-
duction accelerates the onset of the vecuronium neuro-
muscular blockade. They found that the maximum block
in the 8 % sevoflurane group was shorter than that in
the propofol/fentanyl group and the N2O/2 % sevoflur-
ane group (139 ± 35 s, 193 ± 35 s, and 188 ± 47 s, re-
spectively). This finding is contrary to our present
results. In their study, Yamaguchi et al. [18] administered
vecuronium intravenously at 3 min after the start of
anesthetic induction with sevoflurane, and the end-tidal
concentration of sevoflurane reached between 6 and 7 %
in the sevoflurane 8 % group. Tracheal intubation was
performed approximately 2 min after administration of
vecuronium. In our present study, we performed tra-
cheal intubation and assessed the intubation conditions
at 3 min after administration of rocuronium. Thus, the
concentration of sevoflurane could be much less than
that used by Yamaguchi et al. [18].
Cannon et al. [19] reported that patients receiving in-
halational anesthetics require significantly lower vecuro-
nium infusion rates to achieve a 90 % blockade than
those receiving fentanyl, which represents a change in
the pharmacodynamics of vecuronium-induced neuro-
muscular blockade rather than a change in the pharma-
cokinetics. The authors studied the effects of enflurane,
isoflurane, and fentanyl, each in combination with 60 %
nitrous oxide, on the vecuronium infusion rate necessary
to maintain a constant 90 % depression of control
muscle twitch tension. Yamaguchi et al. [18] also re-
ported that the clinical duration from maximal block to
25 % recovery of the TOF ratio in two sevoflurane
groups (2 and 8 %) was longer than that in a propofol/
remifentanil group (47 ± 15, 48 ± 14, and 36 ± 10 min, re-
spectively). Lowry et al. [16] studied the potency and
time course of action of rocuronium in patients anesthe-
tized with 66 % nitrous oxide in oxygen and 1.5 MAC
sevoflurane, isoflurane, or propofol infusion. These au-
thors reported that the mean ED50 and ED95 doses dur-
ing sevoflurane anesthesia were significantly lower than
those during propofol anesthesia. The recovery index
and the times to recovery of Tl to 90 % and TOF ratio
to 0.8 in the sevoflurane group were all significantly lon-
ger than in the propofol group. This accords well with
our current results, where our SEVO groups showed asignificantly longer recovery index than our TIVA
groups at each dose of rocuronium. Furthermore, our
SEVO groups showed a significantly longer recovery
time to T90 than the TIVA groups. We therefore con-
firmed that the type of anesthetic could influence the re-
covery from neuromuscular block.
This study may have several limitations. First, our
study results should be applied only to an Asian popula-
tion. Second, we compared two anesthetic protocols
with sevoflurane-remifentanil and propofol-remifentanil.
Remifentanil infusion with sevoflurane in SEVO group
rather than sevoflurane alone can be a confounding fac-
tor for interpretation of the intubation condition and the
depth of anesthesia. Nevertheless, the reason we adopted
this study design is that the protocol of this study was
based on the daily practice protocol used in the clinical
practice in Korea and Japan, and the results of of our
study can be a real help to them. Third, we did not
present BIS, hemodynamic variable, end-tidal sevoflur-
ane concentration at the time of tracheal intubation. We
considered the anesthetic depth by values measured at
1 min after intubation. There was no significant differ-
ence in diastolic blood pressure, heart rate and BIS ex-
cept systolic blood pressure between groups. Therefore,
we estimated that the same depth of anesthesia was pro-
vided to each group. However, some readers may not
agree on that point. Lastly, sample sizes are approximate
because calculation was based on our clinical assump-
tions not from previous references.
Conclusions
In conclusion, we here demonstrate that to achieve a better
and faster acceptable intubation conditions in Korean and
Japanese patients, 0.9 mg/kg of rocuronium should be ad-
ministered. However, sevoflurane-remifentanil anesthesia
could prolong the recovery from neuromuscular block by
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